Male-to-Female Transsexualism: Technique, Results and 3-Year Follow-Up in 50 Patients

2010 ◽  
Vol 84 (3) ◽  
pp. 330-333 ◽  
Author(s):  
S. Wagner ◽  
F. Greco ◽  
M.R. Hoda ◽  
A. Inferrera ◽  
A. Lupo ◽  
...  
1981 ◽  
Vol 15 (1) ◽  
pp. 45-51 ◽  
Author(s):  
Ira B. Pauly

Fifteen years ago the author reviewed the world literature on male transsexualism (Pauly, 1965). Subsequently he summarized the results of sex reassignment surgery for male and female transsexuals (Pauly, 1968), and reviewed the literature on female transsexualism (Pauly, 1974). Very recently, Meyer and Reter (1979) concluded that ‘sex reassignment surgery confers no objective advantage in terms of social rehabilitation’ as compared with a group of individuals who sought sex reassignment but remained unoperated upon at follow-up. Both groups improved over time and led the Johns Hopkins Gender Identity Clinic to conclude that sex reassignment surgery would no longer be offered there. This report, and other non-surgical, psychotherapeutic approaches to gender dysphoric patients (Barlow et al. 1973; Barlow et al. 1979; Lothstein and Levine, 1980) call into question the justification for sex reassignment surgery. Therefore, it becomes important to update the results of sex reassignment surgery for transsexuals. Data on 283 male to female transsexuals and 83 female to male transsexuals are presented.


2001 ◽  
Vol 88 (4) ◽  
pp. 396-402 ◽  
Author(s):  
S. Krege ◽  
A. Bex ◽  
G. Lümmen ◽  
H. Rübben

BMJ Open ◽  
2013 ◽  
Vol 3 (7) ◽  
pp. e002552 ◽  
Author(s):  
Simone Georges El Khouri Miraglia ◽  
Mariana Matera Veras ◽  
Luis Fernando Amato-Lourenço ◽  
Fernando Rodrigues-Silva ◽  
Paulo Hilário Nascimento Saldiva

2015 ◽  
Vol 8 ◽  
pp. CMED.S31756 ◽  
Author(s):  
Nasrullah K. Ghuman ◽  
Loai M. Saadah ◽  
Majdi S. Al Najjar ◽  
Duha Y. Shaheen ◽  
Shady I. AM ◽  
...  

Objective To measure effectiveness of liraglutide in reducing glycated hemoglobin (HbA1C), weight, and systolic blood pressure (SBP) in Emirati patients. Design A retrospective cohort study. Setting Endocrinology clinic in a 300-bed military hospital. Patients A total of 152 patients who qualified for liraglutide between September 21, 2012, (first patient visit) and May 5, 2014 (last patient visit). Methods Team collected demographic and clinical data using a standard form. Data keeper performed univariate analyses to measure the effect of liraglutide in reducing the three outcomes of interest; namely, HbA1C, weight, and SBP. Results One hundred patients had at least the first visit in the clinic and 98 patients came for a second follow-up visit while on the medication. Adherence of clinicians to the internal criteria for prescribing liraglutide was 92%. Patients' ages were 47.9 ± 11.7 years. Male-to-female ratio was almost 1:1. Overall, in the paired analyses, HbA1C decreased from first to second visits (8.7 ± 1.9 vs. 7.6 ± 1.8, P < 0.0001) and remained unchanged in subsequent visits (eg, in visit 3, HbA1C was 7.4 ± 1.8). Patients lost an average of 1.3 kg between the first and second visits (99.3 ± 19.3 vs. 98.0 ± 19.5, P = 0.0003). The reduction in SBP between visits 1 and 2 was less (130.9 ± 15.8 vs. 129.9 ± 16.5, P = 0.5896). ANOVA yielded a significant reduction in HbA1C at 4 months and 6 months ( P values < 0.05). SBP dropped by about 3.6 mmHg and weight by about 2.3 kg ( P values > 0.05). Conclusions Liraglutide is effective in reducing HbA1C, weight, and to a lesser extent, SBP in Emirati patients.


1985 ◽  
Vol 14 (3) ◽  
pp. 247-261 ◽  
Author(s):  
Ray Blanchard

2008 ◽  
Vol 90 (1) ◽  
pp. 56-59 ◽  
Author(s):  
Eva-Katrin Bentz ◽  
Lukas A. Hefler ◽  
Ulrike Kaufmann ◽  
Johannes C. Huber ◽  
Andrea Kolbus ◽  
...  

2014 ◽  
pp. 15-28
Author(s):  
Ciro Imbimbo ◽  
Davide Arcaniolo

1998 ◽  
Vol 16 (1) ◽  
pp. 70-77 ◽  
Author(s):  
M M Cheung ◽  
J K Chan ◽  
W H Lau ◽  
W Foo ◽  
P T Chan ◽  
...  

PURPOSE To study the clinical features and outcome for primary non-Hodgkin's lymphomas of the nose/nasopharynx (NNP-NHLs) according to immunophenotype. PATIENTS AND METHODS One hundred thirteen Chinese patients with primary NNP-NHLs that belonged to the categories E, F, G, or H according to the Working Formulation (WF), with full immunophenotypic data and complete clinical follow-up data, were analyzed in this retrospective study. RESULTS Ninety (79.6%) patients had localized (stage I or II) disease, while 23 (20.4%) had stage III or IV disease. The lymphomas in 51 (45.1%), 24 (21.3%), and 38 (33.6%) patients showed natural killer (NK)/T- (CD56-positive), T-cell, and B-cell immunophenotype, respectively. Seventy-three patients (65.8%) achieved a complete remission, of whom 34 (46.6%) subsequently relapsed. The median follow-up time for those alive was 88 months. The 5-year actuarial disease-free and overall survival rates were 34.4% and 37.9%, respectively. Multivariate analysis showed that only stage and immunophenotype were significant for survival. NK/T lymphomas were distinctive among the three immunophenotypes in the following aspects: the highest male-to-female ratio, more frequent involvement of the nasal cavity alone, higher risk of dissemination to the skin, more frequent development of hemophagocytic syndrome, and the worst prognosis (overall median survival, 12.5 months). CONCLUSION The three immunophenotypes studied are shown to exhibit different clinical patterns. Since the NK/T phenotype carries the worst prognosis, patients who present with NNP-NHL should have their tumors analyzed for CD56 expression.


Sign in / Sign up

Export Citation Format

Share Document